

# Stephanie E Reuter Lange

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/9042885/stephanie-e-reuter-lange-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

33  
papers

626  
citations

12  
h-index

24  
g-index

40  
ext. papers

805  
ext. citations

4.6  
avg, IF

4.23  
L-index

#	Paper	IF	Citations
33	Accuracy of documented administration times for intravenous antimicrobial drugs and impact on dosing decisions. <i>British Journal of Clinical Pharmacology</i> , <b>2021</b> , 87, 4273-4282	3.8	4
32	The effect of high-dose, short-term caffeine intake on the renal clearance of calcium, sodium and creatinine in healthy adults. <i>British Journal of Clinical Pharmacology</i> , <b>2021</b> , 87, 4461-4466	3.8	0
31	Barriers and opportunities for the clinical implementation of therapeutic drug monitoring in oncology. <i>British Journal of Clinical Pharmacology</i> , <b>2021</b> , 87, 227-236	3.8	6
30	Evaluation of a Pilot Vancomycin Precision Dosing Advisory Service on Target Exposure Attainment Using an Interrupted Time Series Analysis. <i>Clinical Pharmacology and Therapeutics</i> , <b>2021</b> , 109, 212-221	6.1	6
29	Current fluconazole treatment regimens result in under-dosing of critically ill adults during early therapy. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , <b>2021</b> , 40, 1521-1528	5.3	1
28	Model-Optimized Fluconazole Dose Selection for Critically Ill Patients Improves Early Pharmacodynamic Target Attainment without the Need for Therapeutic Drug Monitoring. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2021</b> , 65,	5.9	3
27	Assessment of cefepime toxicodynamics: comprehensive examination of pharmacokinetic/pharmacodynamic targets for cefepime-induced neurotoxicity and evaluation of current dosing guidelines. <i>International Journal of Antimicrobial Agents</i> , <b>2021</b> , 58, 106443	14.3	3
26	Inability of Current Dosing to Achieve Carboplatin Therapeutic Targets in People with Advanced Non-Small Cell Lung Cancer: Impact of Systemic Inflammation on Carboplatin Exposure and Clinical Outcomes. <i>Clinical Pharmacokinetics</i> , <b>2020</b> , 59, 1013-1026	6.2	2
25	A retrospective study to determine the cefepime-induced neurotoxicity threshold in hospitalized patients. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2020</b> , 75, 718-725	5.1	20
24	Ibuprofen for prevention of oxaliplatin-induced acute neurotoxicity: a pilot study assessing preliminary efficacy, tolerability and pharmacokinetic interactions in patients with metastatic gastrointestinal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2020</b> , 86, 547-558	3.5	2
23	Assessing the accuracy of two Bayesian forecasting programs in estimating vancomycin drug exposure. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2020</b> , 75, 3293-3302	5.1	8
22	Development of a physiologically based pharmacokinetic model for intravenous lenalidomide in mice. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2019</b> , 84, 1073-1087	3.5	3
21	Population pharmacokinetics of lenalidomide in patients with B-cell malignancies. <i>British Journal of Clinical Pharmacology</i> , <b>2019</b> , 85, 924-934	3.8	6
20	Optimising time samples for determining area under the curve of pharmacokinetic data using non-compartmental analysis. <i>Journal of Pharmacy and Pharmacology</i> , <b>2019</b> , 71, 1635-1644	4.8	6
19	Comparison of the Area Under the Curve for Vancomycin Estimated Using Compartmental and Noncompartmental Methods in Adult Patients With Normal Renal Function. <i>Therapeutic Drug Monitoring</i> , <b>2019</b> , 41, 726-731	3.2	5
18	Population pharmacokinetics of ribavirin in lung transplant recipients and examination of current and alternative dosing regimens. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2019</b> , 74, 691-698	5.1	2
17	Reducing Palivizumab Dose Requirements Through Rational Dose Regimen Design. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , <b>2019</b> , 8, 26-33	4.5	1

16	Cannabinoid Disposition After Human Intraperitoneal Use: An Insight Into Intraperitoneal Pharmacokinetic Properties in Metastatic Cancer. <i>Clinical Therapeutics</i> , <b>2018</b> , 40, 1442-1447	3.5	7
15	How aOptimalaare Optimal Sampling Times for Tyrosine Kinase Inhibitors in Cancer? Practical Considerations. <i>Clinical Pharmacokinetics</i> , <b>2016</b> , 55, 1171-1177	6.2	4
14	Pharmacokinetics of Cannabis in Cancer Cachexia-Anorexia Syndrome. <i>Clinical Pharmacokinetics</i> , <b>2016</b> , 55, 807-812	6.2	26
13	Pharmacokinetics of a transdermal testosterone cream in healthy postmenopausal women. <i>Menopause</i> , <b>2015</b> , 22, 44-9	2.5	15
12	Effect of food on the pharmacokinetics of piperazine and dihydroartemisinin. <i>Clinical Drug Investigation</i> , <b>2015</b> , 35, 559-67	3.2	19
11	Population pharmacokinetics of orally administered mefloquine in healthy volunteers and patients with uncomplicated Plasmodium falciparum malaria. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2015</b> , 70, 868-76	5.1	12
10	Carnitine and acylcarnitines: pharmacokinetic, pharmacological and clinical aspects. <i>Clinical Pharmacokinetics</i> , <b>2012</b> , 51, 553-72	6.2	222
9	Perceived and actual paracetamol dosing in overweight and obese children. <i>European Journal of Hospital Pharmacy</i> , <b>2012</b> , 19, 438-442	1.6	3
8	Carnitine and Acylcarnitines <b>2012</b> , 51, 553		17
7	Reliability and validity of indices of hand-grip strength and endurance. <i>Australian Occupational Therapy Journal</i> , <b>2011</b> , 58, 82-7	1.7	40
6	Long-chain acylcarnitine deficiency in patients with chronic fatigue syndrome. Potential involvement of altered carnitine palmitoyltransferase-I activity. <i>Journal of Internal Medicine</i> , <b>2011</b> , 270, 76-84	10.8	20
5	Endogenous plasma carnitine pool composition and response to erythropoietin treatment in chronic haemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , <b>2009</b> , 24, 990-6	4.3	28
4	Determination of the reference range of endogenous plasma carnitines in healthy adults. <i>Annals of Clinical Biochemistry</i> , <b>2008</b> , 45, 585-92	2.2	38
3	L-carnitine supplementation in the dialysis population: are Australian patients missing out?. <i>Nephrology</i> , <b>2008</b> , 13, 3-16	2.2	10
2	Impact of haemodialysis on individual endogenous plasma acylcarnitine concentrations in end-stage renal disease. <i>Annals of Clinical Biochemistry</i> , <b>2005</b> , 42, 387-93	2.2	32
1	Impact of hemodialysis on endogenous plasma and muscle carnitine levels in patients with end-stage renal disease. <i>Kidney International</i> , <b>2004</b> , 66, 1527-34	9.9	50